Navigation Links
Revalesio Presents Data Showing RNS60 Alters Disease Progression in Animal Model of Alzheimer's Disease Through the PI3k-Akt Pathway
Date:7/18/2013

TACOMA, Wash., July 18, 2013 /PRNewswire/ -- On Wednesday Revalesio Corporation presented new data at the Alzheimer's Association International Conference that identifies the specific cellular pathways by which Revalesio's lead investigational product, RNS60, impacts Alzheimer's Disease. This research, conducted in partnership with Rush University Medical Center, investigates a new category of therapeutics using Revalesio's novel nanotechnology platform.

Data presented at the conference demonstrated RNS60's ability to prevent memory loss and improve learning through the PI3k-pAKT pathway.  Additionally, RNS60 upregulates critical genes associated with neuronal plasticity.  These genes play a key role in healthy neurotransmitter and synaptic function, foundational activities of the brain. 

Defining RNS60's activity against these genes is an important link between the significant therapeutic activity demonstrated by RNS60 in mouse and cellular models where RNS60 prevented beta-amyloid induced cell death and tau-neurofibrillary tangles – the most common hallmarks of Alzheimer's disease.

"The ability to define RNS60's biological activity to these plasticity associated genes and the PI3k-pAKT-CREB-BDNF pathway is an important event for the company," said Dr. Richard Watson, Revalesio's Chief Science Officer.  "We have a large and expanding data set on RNS60's ability to reduce inflammation, and these findings are a significant advancement in our understanding of how RNS60 may be a treatment for neuro-degenerative diseases."

These plasticity associated genes and associated pathways have long been targets for drug developers, but Revalesio's approach through its charge-stabilized nanostructure technology provides a new paradigm for treating Alzheimer's disease.  Revalesio and its research partners at Rush University Medical Center have submitted the data for publication. 

About RNS60
Revalesio has pioneered the use of RNS60 as a therapeutic that alters whole cell conductance through effects voltage-sensing membrane-bound proteins, thereby modulating the activity of G protein-coupled receptors and the secretion of cytokines, chemokines resulting in decreased inflammation and cell death. RNS60 contains charge-stabilized nanostructures (CSN) that are created by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow. RNS60 has demonstrated a reduction in inflammatory responses that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases. RNS60 has successfully completed Phase I safety studies and is advancing into Phase II clinical trials.

About Revalesio Corporation
Revalesio is a pioneering-clinical stage biomedical company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world to develop RNS60. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is advancing the use of CSN in neuro-inflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit revalesio.com.

Press Contact:
Jesse Thomas
253-926-5567
Email

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Revalesio Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Helen Fisher to Speak at Astellas Presents Executive Womens Day at the Constellation SENIOR PLAYERS Championship
2. Molly Fletcher to Speak at Astellas Presents Executive Womens Day at the AT&T National
3. Lexicon Presents Data at the American Diabetes Association Meeting On Blood Pressure Reduction and Weight Loss In Clinical Trial of LX4211
4. Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract
5. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
6. Pharma IQ Presents the Latest Trends in Clinical Trial Supply
7. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
8. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
9. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
10. Bluestar Silicones Presents Elastomer Solutions At Medical Design And Manufacturing (MD&M) East Show
11. Discovery Labs Presents Final Assessment in a Series of Pharmacoeconomic Analyses that Explore Impact of Reintubation on Healthcare Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Acute lymphocytic ... 2016"  report to their offering.  ... Global Acute Lymphocytic Leukemia Market and ... into Acute Lymphocytic Leukemia pipeline products, Acute ...
(Date:5/3/2016)... TUCSON, Ariz. , May 3, 2016  As ... twice contracted rheumatic fever, which damaged his heart. ... But by June 2013, Shepherd,s heart was ... days from death. On June 20, 2013, the ... temporary Total Artificial Heart (TAH-t). Like a heart transplant, ...
(Date:5/3/2016)... , May 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is ... a video of two patients who tell their personal story and encourage those at risk ... Meet Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... The RIDER ... and development of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against all ... May 3, 2016 at http://igg.me/at/EndTheVirus and runs for 60 days, we ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nike Rugby Camp's success is due ... Diego. Willis, founder of Elite Rugby Camps and current Nike Camp director, has offered ... since 2009. , “I’m excited for our eighth summer here in San Diego,” ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... program created to assist the people of their local community. The agency pledges ... and community leaders. Their hope is to bring awareness to important local causes ...
(Date:5/4/2016)... ... May 04, 2016 , ... Dr. Elyson and Dr. Assili, dentist ... their office. Wisdom tooth removal, a common dental procedure, is performed for many adolescents ... improperly erupted, resulting in risks of complications. By providing wisdom tooth removal surgery at ...
(Date:5/4/2016)... NC (PRWEB) , ... May 04, 2016 , ... Francesca ... N.C., changed her life forever with a same-day LASIK procedure at Christenbury ... poor eyesight. Dr. Jonathan Christenbury performed her surgery the same day as her in-office ...
Breaking Medicine News(10 mins):